ARTICLE | Clinical News
Valtaxin valrubicin chemotherapeutic anthracycline derivative regulatory update
July 24, 2000 7:00 AM UTC
Canada granted marketing approval for PLB's Valtaxin for intravesical therapy of refractory carcinoma in situ (CIS) of the bladder. PLB acquired Canadian rights to the compound, which is marketed in t...